Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA approvals of Gilead’s Sovaldi (sofosbuvir) and Janssen/Medivir’s Olysio (simeprevir), followed by 2014 approvals of Gilead’s Harvoni (sofosbuvir/ledipasvir) and AbbVie’s Viekira Pak (paritaprevir/ombitasvir/ritonavir plus dasabuvir), ushered in the era of interferon (IFN)-free therapy for chronic HCV infections and have completely reshaped the HCV therapeutic market. With the availability of these new agents and the anticipated market entry of other promising emerging therapies in the near term, we expect the treatment landscape for HCV to continue to rapidly evolve with major improvements in drug safety and tolerability, efficacy, compliance, and treatment duration. This report focuses on current and anticipated use of all-oral HCV regimens , IFN-based regimens, and emerging IFN-free regimens by capturing patient market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. For key brands, physician perceived strengths and weaknesses, barriers to uptake, and salesforce performance will be evaluated. Physician awareness, interest, and potential impact of agents in development are also gauged in this study.

Questions Answered in This Report:

  • Insight into current medical practice, diagnosis, referral patterns, and HCV patient load, and characteristics. How are physicians (gastroenterologist, hepatologists, and infectious disease specialists) diagnosing HCV patients, where are these patients referred from, and how have HCV patient loads changed in the last six months (e.g., by genotype, liver severity, treatment experience, prior failed regimen, discontinuation rates)?

  • Physicians have rapidly incorporated new IFN-free regimens in their treatment of HCV patients, including regimens based on Sovaldi, Harvoni, Viekira Pak, and Olysio. How are physicians using currently approved regimens and how is prescribing expected to shift in the next six months? What is driving and hindering product adoption and broader use of drugs?

  • Substantial numbers of HCV patients are seeking treatment with new IFN-free regimens and physicians are tasked with choosing from an increasing variety of highly effective options. How are salesforce teams from the leading HCV brands interacting with physicians? What is the focus of their promotional detailing efforts, and what are their messages for key brands?


Markets covered: United States.

Primary research: 45-minute survey of 50 gastroenterologists, 33 hepatologists, 25 infectious disease specialists.

Population segments in market forecast: treatment-naive, treatment-experienced, cirrhotic, non-cirrhotic, genotype-1, and genotype-2/3.

Author(s): David W. Holman, Ph.D.